
MS2‑p65‑HSF1
$2,400.00 - $4,800.00
All products have special prices for bulk purchase, please contact for more details if required.
Cat. No.: MPH1-500 (for 500pmol)
Cat. No.: MPH1-2500 (for 2500pmol)
Description
MS2‑p65‑HSF1 is a key auxiliary protein component of the Synergistic Activation Mediator (SAM) CRISPRa system, representing a major innovation in second‑generation CRISPR activation technologies. This fusion protein consists of three functional modules: the MS2 bacteriophage coat protein, the NF‑κB p65 transcriptional activation domain, and the heat shock factor 1 (HSF1) activation domain. The MS2 domain specifically recognizes and binds MS2 aptamer sequences embedded within RNA stem‑loop structures, while p65 and HSF1 provide strong transcriptional activation capacity.
In the SAM system, the conventional sgRNA is engineered to include MS2 aptamer sequences within its stem‑loop region. When dCas9‑VP64 is recruited to the promoter of a target gene, these modified sgRNAs simultaneously expose MS2 binding sites, enabling efficient recruitment of the MS2‑p65‑HSF1 fusion protein. The cooperative action of VP64, p65, and HSF1 results in a synergistic enhancement of transcriptional activation, dramatically improving gene‑upregulation efficiency compared with first‑generation CRISPRa systems.
- Potent Gene Activation: Achieving strong transcriptional upregulation using SAM CRISPRa components.
- Multiplexed Gene Activation: Simultaneous activation of multiple genes within a single cell.
- Cell Differentiation Control: Driving cell differentiation or reprogramming by activating lineage‑specific regulators.
- Functional Genomics: Enhanced CRISPRa‑based screening for gain‑of‑function studies.
- HIV Latency Reversal: Activating latent HIV proviruses for “shock‑and‑kill” therapeutic research.
SBS Genetech is recognized as one of the global major leading industry players in Gene Editing by third-party market researchers. For more details, please visit Global Gene Editing Service Market 2019 by Company, Regions, Type and Application, Forecast to 2024.
Related:
- Synthetic sgRNAs
- Cas12a Nuclease (Lyophilized)
- Cas12b Nuclease (Lyophilized)
- Cas13a Nuclease (Lyophilized)
- Cas14a1 Nuclease (Lyophilized)
- SpCas9 Nuclease (Lyophilized)
- SuCas12a2 Nuclease (Lyophilized)
- dCas9 NLS (Lyophilized)
- EiCsm6 (Lyophilized)
- LwaCas13a Nuclease (Lyophilized)
- BrCas12a Nuclease (Lyophilized)
- AsCas12a Nuclease (Lyophilized)
- Cas9 Nuclease (with NLS)
- Cas9 HF-NLS (SpCas9 HF-NLS)
- CRISPR-dCas9 Nuclease
- dCas9 NLS
- spCas9
- SpdCas9
- spCas9-NG
- SpRYCas9
- Cas9 Nickase (H840A) NLS
- Cas9 Nickase (D10A) NLS
- TsCas12a
- OsCas12a
- HkCas12a
- BoCas12a
- AsCas12a
- FnCas12a
- LbCas12a (Cpf1) Nuclease
- Enhanced LbaCas12a (Cpf1)
- Lb5Cas12a (Cpf1) Nuclease
- SuCas12a2 Nuclease
- AaCas12b
- AacCas12b
- AapCas12b
- BrCas12b
- LwCas13a
- LbuCas13a
- LtrCas13a (C2c2) Nuclease
- LwaCas13a (C2c2) Nuclease
- EiCsm6
- HheCas13a (C2c2)
- TccCas13a (C2c2)
- YmeCas12a (Cpf1)
- CmeCas12a (Cpf1)
- Enhanced LbCas12a
- PfAgo
- TtAgo
- T7 Endonuclease I










